المؤلفون: Tomoyuki Otsuka, Sumiyuki Nishida, Takayuki Shibahara, Burcu Temizoz, Masanari Hamaguchi, Takayuki Shiroyama, Keiko Kimura, Kotaro Miyake, Haruhiko Hirata, Yumiko Mizuno, Mayu Yagita, Yusuke Manabe, Etsushi Kuroda, Yoshito Takeda, Hiroshi Kida, Ken J. Ishii, Atsushi Kumanogoh

المصدر: BMC Cancer, Vol 22, Iss 1, Pp 1-15 (2022)

مصطلحات موضوعية: Cytosine-phosphate-guanine oligodeoxynucleotide, Toll-like receptor 9 agonist, Lung cancer, Immunotherapy, Dose-limiting toxicity, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2407Test

الوصول الحر: https://doaj.org/article/8812c8d7ce2f4eff8b8439c505989aa3Test

المؤلفون: Niclas Stefan Rasmussen, Christoffer Tandrup Nielsen, Søren Jacobsen, Claus Henrik Nielsen

المصدر: Frontiers in Immunology, Vol 10 (2019)

مصطلحات موضوعية: peripheral blood mononuclear cells, T cells, microvesicles, Toll-like receptor 9 agonist, type 1 interferon, galectin-3 binding protein, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/article/10.3389/fimmu.2019.02391/fullTest; https://doaj.org/toc/1664-3224Test

الوصول الحر: https://doaj.org/article/2f04433ec2834c25a2ca677c53fc5245Test

المؤلفون: Vibholm, Line K., Konrad, Christina V., Schleimann, Mariane H., Frattari, Giacomo, Winckelmann, Anni, Klastrup, Vibeke, Jensen, Nanna M., Schmidt, Manuel, Wittig, Burghardt, Zuwala, Kaja, Mack, Katharina, Olesen, Rikke, Hua, Stephane, Lichterfeld, Mathias, Østergaard, Lars, Denton, Paul W., Tolstrup, Martin, Søgaard, Ole S.

المصدر: Vibholm , L K , Konrad , C V , Schleimann , M H , Frattari , G , Winckelmann , A , Klastrup , V , Jensen , N M , Schmidt , M , Wittig , B , Zuwala , K , Mack , K , Olesen , R , Hua , S , Lichterfeld , M , Østergaard , L , Denton , P W , Tolstrup , M & Søgaard , O S 2019 , ' Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals ' , AIDS (London, England) , ....

مصطلحات موضوعية: AIDS, ANTIRETROVIRAL THERAPY, CHEMOTHERAPY, DECAY KINETICS, HIV cure, HIV type 1, INFECTED PATIENTS, INTERRUPTION, LATENT RESERVOIR, MGN1703, T-LYMPHOCYTES, TLR9 AGONIST, Toll-like receptor 9 agonist, cellular immunity, immunotherapy, investigational therapy

العلاقة: https://pure.au.dk/portal/en/publications/39a77657-f724-4206-a780-5a6b6139fc80Test

الإتاحة: https://doi.org/10.1097/QAD.0000000000002213Test
https://pure.au.dk/portal/en/publications/39a77657-f724-4206-a780-5a6b6139fc80Test
http://www.scopus.com/inward/record.url?scp=85067089864&partnerID=8YFLogxKTest

المؤلفون: Ole Schmeltz Søgaard, Manuel Schmidt, Burghardt Wittig, Kaja Zuwala, Martin Tolstrup, Mariane H. Schleimann, Stephane Hua, Katharina Mack, Rikke Olesen, Anni Winckelmann, Line K. Vibholm, Mathias Lichterfeld, Sanne Skov Jensen, Vibeke Klastrup, Giacomo S. Frattari, Paul W. Denton, Nanna M. Jensen, Lars Østergaard, Christina V. Konrad

المصدر: Vibholm, L K, Konrad, C V, Schleimann, M H, Frattari, G, Winckelmann, A, Klastrup, V, Jensen, N M, Schmidt, M, Wittig, B, Zuwala, K, Mack, K, Olesen, R, Hua, S, Lichterfeld, M, Østergaard, L, Denton, P W, Tolstrup, M & Søgaard, O S 2019, ' Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals ', AIDS (London, England), vol. 33, no. 8, pp. 1315-1325 . https://doi.org/10.1097/QAD.0000000000002213Test

مصطلحات موضوعية: CD4-Positive T-Lymphocytes, Male, Cellular immunity, medicine.medical_treatment, TLR9 AGONIST, HIV Infections, law.invention, Randomized controlled trial, ANTIRETROVIRAL THERAPY, T-LYMPHOCYTES, law, Immunology and Allergy, Medicine, Aged, 80 and over, INFECTED PATIENTS, HIV cure, MGN1703, Middle Aged, Viral Load, CHEMOTHERAPY, Acquired immune system, Toll-like receptor 9 agonist, investigational therapy, AIDS, Treatment Outcome, Infectious Diseases, Female, immunotherapy, Viral load, Adult, Agonist, Drug-Related Side Effects and Adverse Reactions, medicine.drug_class, Immunology, Viremia, cellular immunity, Young Adult, Immune system, LATENT RESERVOIR, DECAY KINETICS, Humans, Immunologic Factors, Aged, INTERRUPTION, business.industry, DNA, Immunotherapy, medicine.disease, Toll-Like Receptor 9, HIV-1, business, HIV type 1

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97789671b5831b91f2f21413c994b460Test
https://pure.au.dk/portal/da/publications/effects-of-24week-tolllikeTest-receptor-9-agonist-treatment-in-hiv-type-1-individuals(39a77657-f724-4206-a780-5a6b6139fc80).html

المؤلفون: Niclas Stefan Rasmussen, Christoffer Tandrup Nielsen, Søren Jacobsen, Claus Henrik Nielsen

مصطلحات موضوعية: Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, peripheral blood mononuclear cells, T cells, microvesicles, Toll-like receptor 9 agonist, type 1 interferon, galectin-3 binding protein, dsDNA, systemic lupus erythematosus

العلاقة: https://figshare.com/articles/dataset/Data_Sheet_1_Stimulation_of_Mononuclear_Cells_Through_Toll-Like_Receptor_9_Induces_Release_of_Microvesicles_Expressing_Double-Stranded_DNA_and_Galectin_3-Binding_Protein_in_an_Interferon-_-Dependent_Manner_pdf/9968636Test

الإتاحة: https://doi.org/10.3389/fimmu.2019.02391.s001Test
https://figshare.com/articles/dataset/Data_Sheet_1_Stimulation_of_Mononuclear_Cells_Through_Toll-Like_Receptor_9_Induces_Release_of_Microvesicles_Expressing_Double-Stranded_DNA_and_Galectin_3-Binding_Protein_in_an_Interferon-_-Dependent_Manner_pdf/9968636Test

مصطلحات الفهرس: human, immune response, infection, inflammation, kidney carcinoma, lung non small cell cancer/dt [Drug Therapy], melanoma, multiple sclerosis/dt [Drug Therapy], psoriasis/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], sepsis/dt [Drug Therapy], signal transduction, tissue injury, tumor, cathelicidin/dv [Drug Development], cathelicidin antimicrobial peptide LL 37, CpG 7909/dv [Drug Development], CpG 7909/dt [Drug Therapy], flagellin, heat shock protein 10/dt [Drug Therapy], imiquimod/ct [Clinical Trial], imiquimod/dv [Drug Development], imiquimod/tp [Topical Drug Administration], influenza vaccine/cb [Drug Combination], influenza vaccine/dt [Drug Therapy], influenza vaccine/pd [Pharmacology], lipid A derivative/dt [Drug Therapy], lipid A derivative/pd [Pharmacology], rituximab/cb [Drug Combination], toll like receptor, toll like receptor 7/dv [Drug Development], unclassified drug, Wart virus vaccine/ct [Clinical Trial], Wart virus vaccine/dt [Drug Therapy], ana 773, ana 975, ave 0675, ave 7279, cationic lipid/dv [Drug Development], cq 07001/ct [Clinical Trial], cq 07001/dv [Drug Development], crx 675/ct [Clinical Trial], crx 675/dt [Drug Therapy], crx 675/tp [Topical Drug Administration], e 5564, eritoran/ct [Clinical Trial], eritoran/dv [Drug Development], eritoran/dt [Drug Therapy], eritoran/pd [Pharmacology], Flagellin huha, Flagellin hum2e, heplislav/dv [Drug Development], imo 2055/dv [Drug Development], imo 2055/dt [Drug Therapy], iph 31xx/dv [Drug Development], iph 32xx/dv [Drug Development], mct 465/dv [Drug Development], ph 31xx, ph 32xx, resatorvid/dv [Drug Development], sotorabine/ct [Clinical Trial], tak 242, tolamba/ct [Clinical Trial], tolamba/dv [Drug Development], toll like receptor 3 agonist, toll like receptor 9 agonist/cb [Drug Combination], toll like receptor 9 agonist/dv [Drug Development], toll like receptor 9 agonist/dt [Drug Therapy], toll like receptor 9 agonist/pd [Pharmacology], vaximmune/ct [Clinical Trial], vaximmune/dv [Drug Development], review, immunity, actinic keratosis/dt [Drug Therapy], allergic reaction, allergic rhinitis/dt [Drug Therapy], autoimmune disease, basal cell carcinoma/dt [Drug Therapy], biotechnology, clinical trial, colorectal cancer/dt [Drug Therapy], condyloma/dt [Drug Therapy], cutaneous T cell lymphoma, drug synthesis, drug targeting, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31883Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: human, immune response, infection, inflammation, kidney carcinoma, lung non small cell cancer/dt [Drug Therapy], melanoma, multiple sclerosis/dt [Drug Therapy], psoriasis/dt [Drug Therapy], rheumatoid arthritis/dt [Drug Therapy], sepsis/dt [Drug Therapy], signal transduction, tissue injury, tumor, cathelicidin/dv [Drug Development], cathelicidin antimicrobial peptide LL 37, CpG 7909/dv [Drug Development], CpG 7909/dt [Drug Therapy], flagellin, heat shock protein 10/dt [Drug Therapy], imiquimod/ct [Clinical Trial], imiquimod/dv [Drug Development], imiquimod/tp [Topical Drug Administration], influenza vaccine/cb [Drug Combination], influenza vaccine/dt [Drug Therapy], influenza vaccine/pd [Pharmacology], lipid A derivative/dt [Drug Therapy], lipid A derivative/pd [Pharmacology], rituximab/cb [Drug Combination], toll like receptor, toll like receptor 7/dv [Drug Development], unclassified drug, Wart virus vaccine/ct [Clinical Trial], Wart virus vaccine/dt [Drug Therapy], ana 773, ana 975, ave 0675, ave 7279, cationic lipid/dv [Drug Development], cq 07001/ct [Clinical Trial], cq 07001/dv [Drug Development], crx 675/ct [Clinical Trial], crx 675/dt [Drug Therapy], crx 675/tp [Topical Drug Administration], e 5564, eritoran/ct [Clinical Trial], eritoran/dv [Drug Development], eritoran/dt [Drug Therapy], eritoran/pd [Pharmacology], Flagellin huha, Flagellin hum2e, heplislav/dv [Drug Development], imo 2055/dv [Drug Development], imo 2055/dt [Drug Therapy], iph 31xx/dv [Drug Development], iph 32xx/dv [Drug Development], mct 465/dv [Drug Development], ph 31xx, ph 32xx, resatorvid/dv [Drug Development], sotorabine/ct [Clinical Trial], tak 242, tolamba/ct [Clinical Trial], tolamba/dv [Drug Development], toll like receptor 3 agonist, toll like receptor 9 agonist/cb [Drug Combination], toll like receptor 9 agonist/dv [Drug Development], toll like receptor 9 agonist/dt [Drug Therapy], toll like receptor 9 agonist/pd [Pharmacology], vaximmune/ct [Clinical Trial], vaximmune/dv [Drug Development], review, immunity, actinic keratosis/dt [Drug Therapy], allergic reaction, allergic rhinitis/dt [Drug Therapy], autoimmune disease, basal cell carcinoma/dt [Drug Therapy], biotechnology, clinical trial, colorectal cancer/dt [Drug Therapy], condyloma/dt [Drug Therapy], cutaneous T cell lymphoma, drug synthesis, drug targeting, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/31883Test
LibKey Link